What Bergamo does

Bergamo Farmacêutica is a Brazilian pharmaceutical manufacturer founded in 1916, headquartered at a single manufacturing plant in Taboão da Serra, São Paulo. The company develops, manufactures, and commercializes generic and similar pharmaceutical products organized across three product lines: Onco-Hematology (70% of portfolio), Hospital Segment, and General Medicine (combined 30%). Its portfolio of 23 medications includes injectable oncology and hematology products, hospital-administered injectables, and broader general-medicine therapies. Bergamo operates a single integrated manufacturing facility with capabilities spanning raw materials through finished product, including two lyophilizers for freeze-dried injectables installed (second unit in 2019). Its underlying technology platform centers on Quality by Design (QbD) methodology, Lean manufacturing, and a Pull System (Kanban) production approach — Bergamo was the first site within Amgen's global network to implement pull-based production across all manufacturing processes.

The company's business model is built on pharmaceutical product sales through direct field sales to healthcare institutions and hospitals, distribution via Brazilian pharmacy networks, and an online order portal for existing clients (pedidosbergamo.com.br). It operates complementary service channels including a Scientific Information Service (SIC), pharmacovigilance reporting, and the LogMed reverse-logistics program. With approximately 180 employees running three shifts, Bergamo distributed roughly 3 million units in 2022 and has maintained zero product recalls for over 10 years. The company was owned by Amgen from 2011 to 2022, during which approximately R$50 million was invested in the factory and international quality standards were embedded. In 2023, Bergamo was acquired by Blau Farmacêutica, creating a combined group with one of Brazil's largest onco-hematology portfolios and production capacities. Bergamo has begun international expansion, obtaining Invima certification for the Colombian market in 2021.

Name

Bergamo

Legal name

Laboratório Químico Farmacêutico Bergamo Ltda.

Website

https://bergamobrasil.com.br

Company type

Private

Founded year

1916

Operating status

Operating

Headcount range

1–10 employees

Short description

Bergamo Farmacêutica is a Brazilian pharmaceutical manufacturer specializing in generic and similar injectable medicines, with 70% of its 23-product portfolio focused on onco-hematology, serving hospitals, healthcare institutions, and pharmacies in Brazil.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Oncology injectable drugs
• Onco-hematology treatments
• Hospital medications
• Lyophilized pharmaceuticals

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Bergamo develops, manufactures, and commercializes generic and similar pharmaceutical products across three therapeutic lines (onco-hematology, hospital, general medicine). Revenue is generated through direct sales to healthcare institutions and distribution through pharmacies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Bergamo Farmacêutica develops, manufactures, and commercializes generic and similar pharmaceutical products in Brazil, organized into three therapeutic lines: onco-hematology injectable products (70% of portfolio), hospital-use injectable medications, and general medicines. The company operates a manufacturing plant in Taboão da Serra (São Paulo) producing approximately 23 medications and ~3 million units annually, distributed to hospitals, clinics, and pharmacies.

Product overview

Bergamo Farmacêutica is a Brazilian pharmaceutical company specializing in generic and similar medicines, organized into three main product lines: Onco-Hemato (representing 70% of the portfolio with injectable oncology and hematology products), Hospitalar (hospital segment products), and Medicina Geral (general medicine). The company operates a manufacturing plant in Taboão da Serra, SP, producing approximately 23 medications. Beyond its core pharmaceutical products, Bergamo offers complementary services including a Scientific Information Service (SIC), reverse logistics for medications (Logística Reversa), an online order portal (Portal de Pedidos), and a factory open house program (Programa Portas Abertas). The company was acquired by Blau Farmacêutica in 2023 after previously being part of Amgen from 2011-2022.

Differentiator

Problem solved

Functional benefit

Products and services

• Onco-Hemato Products Generic and similar injectable pharmaceutical products for oncology and hematology treatment, representing 70% of the company's portfolio. Focuses on high-prevalence cancers and provides multiple therapy options for comprehensive patient care, intended for healthcare institutions and hospitals.
• Medicina Geral (General Medicine Products) Generic and similar medicines for general medical conditions, part of the 30% non-oncology portfolio. Developed in strategic waves to bring solutions by treatment areas and types, intended for distribution through pharmacies and healthcare institutions.
• Hospitalar (Hospital Segment Products) Pharmaceutical products specifically designed for hospital use, representing 30% of the portfolio alongside general medicine. Focuses on injectable formulations and complex drug delivery technologies for hospital-administered treatments.
• Logística Reversa de Medicamentos Reverse logistics service for expired or unused medications and their packaging (MDVD). Ensures environmentally appropriate disposal through the Sistema Logmed collective plan, operated jointly with pharmaceutical industry, distribution, and retail partners.
• Portal de Pedidos Online order portal allowing healthcare institution and pharmacy customers to place and track pharmaceutical orders. Access is restricted to registered Bergamo clients.

Quantifiable outcome

• Zero product recalls for over 10 years
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core and minor.

• LogMed (Sistema Logmed)coreStrategic or Co-development Partner · 1 January 2021Bergamo participates in the collective plan operated by LogMed for reverse logistics of expired or unused medicines and their packaging. The system is operated jointly by industry, distribution, and retail sectors. From June 2021 to October 2022, Logmed collected more than 195 tons of products.
• AmgencoreStrategic or Co-development Partner · 1 January 2011Bergamo was owned by Amgen from 2011 to 2022. During this period, Amgen implemented international quality processes, invested R$50 million in the factory, and helped Bergamo assimilate know-how to become a strategic company in the health sector.
• Blau FarmacêuticacoreStrategic or Co-development PartnerAcquired Bergamo in 2023. Together, the group formed by the companies has one of the most complete portfolios in the onco-hematology segment, in addition to one of the largest production capacities in Brazil.
• Interfarma (Associação da Indústria Farmacêutica de Pesquisa)minorStrategic or Co-development PartnerPartner entity in the LogMed reverse logistics system
• Sindusfarma (Sindicato da Indústria de Produtos Farmacêuticos)minorStrategic or Co-development PartnerPartner entity in the LogMed reverse logistics system
• ChemocoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products. Bergamo has partnerships with companies of different nationalities in co-development and licensing of finished products.
• Dong-a PharmcoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• MedytoxcoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• MSNcoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• NaprodcoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• XelliacoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• GalenicumcoreStrategic or Co-development PartnerDrug delivery technology partner for co-development and licensing of complex products
• EEP HCFMUSPminorStrategic or Co-development PartnerPartnership for pharmaceutical preceptorships with Escola de Educação Permanente dos Hospital das Clínicas – Faculdade de Medicina da Universidade de São Paulo
• ICESPminorStrategic or Co-development PartnerPartnership for pharmaceutical preceptorships with Instituto do Câncer do Estado de São Paulo

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bergamo